Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Ryan Michael Reyes"'
Autor:
Tyler Curiel, Yilun Deng, Aravind Kancharla, Myrna Garcia, Haiyan Bai, Ryan Michael Reyes, Harshita B Gupta, Alvaro S Padron, Anand V R Kornepati, Jose R Conejo-Garcia, Yiji J Liao, Clare J Murray, Carlos Ontiveros, Suresh J Kari
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 2 (2023)
Background Tumor intracellular programmed cell death ligand-1 (PDL1) mediates pathologic signals that regulate clinical treatment responses distinctly from surface-expressed PDL1 targeted by αPDL1 immune checkpoint blockade antibodies.Methods We per
Externí odkaz:
https://doaj.org/article/17e6b1fa8654420fb479e0007b231c94
Autor:
Yilun Deng, Aravind Kancharla, Myrna Garcia, Deyi Zhang, Niannian Ji, Neelam Mukherjee, Karen Wheeler, Tyler J Curiel, Robert S Svatek, Ryan Michael Reyes, Harshita B Gupta, Alvaro S Padron, Chenghao Zhang, Anand V R Kornepati, Onur Boyman, Jose R Conejo-Garcia
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 4 (2021)
Background Anti-programmed death-ligand 1 (αPD-L1) immunotherapy is approved to treat bladder cancer (BC) but is effective in
Externí odkaz:
https://doaj.org/article/2a231be16e8747f5b3befb1e7bde6cde
Autor:
Haiyan Bai, Alvaro S Padron, Yilun Deng, Yiji J Liao, Clare J Murray, Carlos Ontiveros, Suresh J Kari, Aravind Kancharla, Anand V R Kornepati, Myrna Garcia, Ryan Michael Reyes, Harshita B Gupta, Jose R Conejo-Garcia, Tyler Curiel
Publikováno v:
Journal for ImmunoTherapy of Cancer. 11:e004871
BackgroundTumor intracellular programmed cell death ligand-1 (PDL1) mediates pathologic signals that regulate clinical treatment responses distinctly from surface-expressed PDL1 targeted by αPDL1 immune checkpoint blockade antibodies.MethodsWe perfo
Autor:
Ryan Michael Reyes, Yilun Deng, Deyi Zhang, Neelam Mukherjee, Niannian Ji, Karen Wheeler, Harshita B. Gupta, Myrna Garcia, Anand Kornepati, Robert S Svatek, Tyler J Curiel
Publikováno v:
The Journal of Immunology. 204:88.14-88.14
αPD-L1 bladder cancer (BC) immunotherapy is effective in
Autor:
Ryan Michael Reyes, Deyi Zhang, Yilun Deng, Neelam Mukherjee, Niannian Ji, Harshita B Gupta, Robert S Svatek, Tyler J Curiel
Publikováno v:
The Journal of Immunology. 202:136.14-136.14
αPD-L1 is an FDA-approved bladder cancer (BC) immunotherapy but is effective in ≤30% of cases. We tested conjugates of αIL-2 antibody + IL-2 (IL-2c) that block IL-2 from binding high-affinity IL-2Rα (CD25) for preferential IL-2Rβ(CD122) binding
Autor:
Yilun Deng, Harshita B. Gupta, Justin Michael Drerup, Ryan Michael Reyes, Jenny Mendez, Xinyue Zhang, Alvaro S Padron, Myrna Garcia, Tyler J Curiel
Publikováno v:
The Journal of Immunology. 202:136.15-136.15
Anti-tumor T cells (Teffs) engage IL2 largely through CD122, vs. CD25 for regulatory T cells (Tregs). In ID8agg ovarian cancer (OC), CD122-selective IL2 complexes (IL2c, made from CD122-blocking ab+IL-2), increased Teff numbers and functions as expec